Abstract One of the hallmarks of human solid tumors is chromosomal instability (CIN). We studied global patterns as well as individual levels of CIN and determined the prognostic relevance among breast cancer subtypes. For this, we used single nucleotide polymorphism copy number data of 313 primary lymph-node negative breast cancers. The level of CIN for individual samples was determined by counting the total number of chromosomal segments showing a gain or loss per specimen. Hierarchical clustering resulted in four groups showing distinct patterns of abnormalities, predominantly characterized by 1q gain, 8q gain, 1q&8q gain, or no gain of these loci. Estrogen receptor (ER)-positive and ER-negative samples showed an uneven distribution (statistically significant) across the cluster-groups, as did the molecular subtypes and triplenegative tumors (negative for estrogen-, progesterone-, and her2/neu-receptor). The CIN-score was significantly higher in ER-negative and triple-negative samples. Among luminal cancers, luminal B had a higher CIN-score than luminal A. The CIN-score was significantly associated with prognosis, measured by the time to distant metastasis, in ER-positive, luminal B, and her2/neu subtypes, but not in ER-negative patients. Our study points to a multifaceted role for CIN in breast cancer. Within ER-negative samples, CIN is likely related to the onset but other factors govern the progression of the disease. In contrast, CIN is clearly associated with progression in ER-positive, luminal B, and her2/neu subtypes; thus, assessing CIN in these subtypes may contribute to personalized patient management.
Introduction
Chromosomal instability (CIN) is a well-known phenomenon observed in many types of cancer and has a pivotal role in tumor onset and progression [1] . With respect to breast cancer, literature concerning CIN is mostly based on comparative genomic hybridization (CGH) techniques, which have demonstrated specific gains and losses of chromosomal areas in diverse breast cancer subtypes [2] [3] [4] [5] [6] [7] [8] . In addition, Carter et al. [9] have shown that a gene expression profile associated with the incidence of CIN has prognostic relevance in breast cancer. However, this latter study was based on a diverse panel of cancer cell lines and by establishing CIN through a gene expression profile; thus, CIN was assessed indirectly [9] . Very recently, whole genome paired-end sequencing data of breast cancer samples showed complex somatic rearrangements with some samples showing a large number of deletions, tandem duplications, or amplifications, while other samples have virtually no rearrangements [10] .
In this study, we investigated the patterns and prevalence of CIN in subtypes of breast cancer and the relevance of these two measures of CIN with respect to patient outcome. To this end, we used a high-resolution 100K single nucleotide polymorphism (SNP) microarray dataset of 313 lymph-node negative primary breast cancer patients with known outcome [11] . Since the patients in this retrospective cohort did not receive any kind of adjuvant systemic therapy after surgery, this study addresses the pure prognostic value, without the potential confounding effects of therapy. Hierarchical clustering showed four groups with a distinct landscape of abnormalities. We elaborated on this by devising a CIN-score for individual samples. This CIN-score was determined by enumerating the total number of genomic areas that showed a concordant loss or gain according to the copy number of the SNPs present therein. Given the well-known clinical relevance of the diverse breast cancer subtypes such as the five molecular subtypes [12] , estrogen receptor (ER)-positive and -negative diseases [11, [13] [14] [15] as well as triple-negative disease (negative for ER, progesterone receptor (PR) and her2/ neu), we analyzed the CIN-score and its association with prognosis in these pathological and molecular subtypes. Our data provide evidence for a highly unstable genome in ER-negative, triple-negative, and basal-like tumors, whereas prognostic relevance is only present in patients with ER-positive breast cancer and of the luminal B and her2/neu subtype. Furthermore, to understand the biology related to CIN, we tested whether biologically meaningful pathways are related to CIN in ER-positive breast cancer, the cancer subtype in which CIN was strongly prognostic.
Materials and methods

Patient and tumor material
Primary tumors of lymph node-negative breast cancer patients were stored in liquid nitrogen at the Erasmus Medical Center. 344 tumors of which Affymetrix U133a gene expression data were available [15, 16] were initially selected for subsequent analysis of DNA copy number alteration using Affymetrix GeneChip Mapping 100K Array Set (Affymetrix, Santa Clara, CA, USA). Goodquality DNA was available for hybridization of 328 of the 344 tumors and reliable SNP calls could be obtained from 313 of these tumors, which were included in the previous analysis of copy number alteration [11] and in this study on CIN. All 313 patients were treated from 1980 to 1995 with the same guidelines for local primary treatment, implying that none of these patients did receive any systemic (neo)adjuvant therapy. Patients who first developed a local recurrence before distant metastasis were not included to avoid the possibility that the distant metastasis later on could have originated from the local recurrence. The study was approved by the medical ethics committee of Erasmus MC (MEC 02.953) and conducted in accordance to the code of conduct of Federation of Medical Scientific Societies in the Netherlands (www.fmwv.nl). Whenever possible, we adhered to the Reporting Recommendations for Tumor Marker Prognostic Studies REMARK [17] . Full clinical and pathological characteristics are described elsewhere [11] . Briefly, mean age at surgery was 54 years (standard deviation 12 years), 49% of patients were premenopausal, 201 tumors were ER positive (according to expression measured on microarray [18] ), and 112 ER negative. Of all surviving patients (n = 220), median follow-up time was 99 months (range 20-169 months). Of the 313 included patients, 114 (36%) developed a distant metastasis, of whom 77 were ER-positive and 37 ER-negative.
DNA copy number analysis and CIN-score All tumors were confirmed to have sufficient ([70%) tumor content. The CIN-score was established using SNPs present on the Affymetrix GeneChip Mapping 100K Array Set (Affymetrix, Santa Clara, CA, USA). Copy number data was obtained using previously described methods [11] and is available in the National Center for Biotechnology Information/Gene Expression Omnibus database (GEO) entry GSE10099. For each SNP, the estimate diploid copy number was established [11] and the distance of the actual copy number for that SNP to the estimate was calculated for each tumor. Hierarchical clustering of copy number data was performed using Nexus (BioDiscovery, El Segundo, CA, USA). For the CIN-score, a SNP was called gain or loss, if the copy number was 0.4 higher or lower than the estimate diploid copy number, respectively. This cut-off was established using Nexus by visual inspection of many samples showing a gain of a complete chromosomal arm. Next, for each patient, the number of genomic segments showing CIN was counted. A CIN-area met these criteria; presence of at least 2 SNPs and sequential SNPs lied within 100-kb distance. Then the status of the SNPs was classified as either ''gain,'' ''loss,'' or ''normal.'' Due to the inherited noise within these arrays, one normal-call was allowed within two SNPs having a gain (or loss) call. Thus, two sequential SNPs with a ''normal'' call signaled the end of that area. Likewise if a ''gain'' SNP followed a ''loss'' SNP, or vice versa. The total number of affected areas in a tumor genome was considered a reliable measure for CIN. We tested if the CIN-score was influenced by the selected criteria. First, the maximum of 100-kb distance between two sequential SNPs was omitted. The resulting CINscores had a Pearson correlation of 0.946 with the original score. Similarly, when including regions which had only a single SNP showing gain or loss, the Pearson correlation with the original score was 0.998. Thus, irrespective of the inclusion criteria, highly consistent CIN-scores were retrieved. In our view, the CIN-score based on including the 100-kb distance criterion and exclusion of single SNP regions is less likely to be overly optimistic and was therefore used in this study.
Gene expression data mRNA expression data available for this entire cohort [15, 16] were used to establish ER, PR, and ERBB2 status, to determine the intrinsic molecular subtypes [12, 19] , to associate genes with CIN and to conduct pathway analysis. Gene Set Enrichment Analysis (GSEA) [20] was used to identify which of the public gene profiles as described in the database (http://www.broad.mit.edu/gsea/msigdb/index. jsp) complemented with the prognostic breast cancer gene sets [9, 12, 14, 15, [21] [22] [23] [24] [25] [26] , are associated with the CINscores. Using default parameters, ER-positive samples with the top 25% CIN-scores were compared to the bottom 25% CIN-scores of ER-positive samples (50 samples in each group). Next, the genes within the public profiles were assessed to see if they were significantly enriched in the top (or bottom) ranked order of significant genes. The Global Test [27] program was used (version 4.2.0) to associate Biocarta pathways (http://www.biocarta.com) to the same sample-groups as were used in the GSEA analysis. SAM analysis [28] was used to identify differentially expressed genes between the samples with the highest and lowest CIN-scores (50 samples in each group for ER-positive tumors and 28 samples in each group for ER-negative tumors). Independent datasets [25, 29] were downloaded from GEO (GSE11121 and GSE2990) and processed with the same parameters as our own dataset [15, 16] . The top 40 significant genes (20 genes higher expressed in high CIN and 20 genes higher expressed in low CIN tumors) were selected and were used in BRB-ArrayTools (v3.7.1 developed by Dr. Richard Simon and the BRB-ArrayTools Development Team) using the Compound Covariate Predictor to predict the status of the samples in the external datasets as ''high CIN'' or ''low CIN''. Our samples were used as training data.
STATA, release 10.1 (StataCorp, Texas, USA), was used to calculate the Cox proportional HR. MFS was used as endpoint and was defined as the first detection of a distant metastasis that was confirmed after symptoms were reported by the patient or when clinical signs of metastasis were detected at regular follow-up. Each of the subgroups showed a sufficient number of events (more than 20) to use the HR tests, except for the normal-like subtype (7 events). Log-rank tests for trend were used to test the equality of survivor functions across more than two groups. A two-sided P value of \0.05 was considered statistically significant.
Results
CIN distribution among breast cancer subtypes
Unsupervised hierarchical clustering of SNP copy number data of 313 breast cancer patients identified four main groups, of which the frequency of copy number alterations are shown in Fig. 1 . Most striking features of the clustered groups were the large percentage of samples showing a gain of either chromosome (chr) 8q (first cluster), chr 1q (cluster 4), or both (second cluster-group). Association of these cluster-groups with diverse subtypes shows a highly Table 1 ). Figure 1 also makes clear that a large variety in chromosomal instabilities is present in the different samples (see supporting information; Online Resource Fig. 1 for 2 extreme examples). We found no significant differences in prognosis between the four cluster-groups (Online Resource Fig. 2 ). We next established a CIN-score for each individual sample. The CIN-score in our cohort ranged from 66 to 3380 (median 907). ER-negative tumors, as well as the triple-negative tumors, had significantly higher CIN-scores than those that were positive for one or more of these receptors (Mann-Whitney test P \ 0.0001 in both analyses) (Fig. 2a, b) . Among the intrinsic subtypes, basal and luminal B cancers had higher CIN-scores (Fig. 2c) . A Kruskal-Wallis test for difference in median levels between all the molecular subgroups was significant, P \ 0.0001. Furthermore, post hoc pairwise comparisons (Bonferroni corrected for multiple testing) of the subtypes showed a significant difference in median CIN-scores of basal versus luminal B samples (P = 0.001). In fact, all pairwise comparisons were significant (P = 0.005 or lower), except for her2/neu versus luminal A, her2/neu versus luminal B, and luminal A versus normal-like.
CIN and prognosis
Next, we related the CIN-score to prognosis in the various subtypes. Of the 313 patients, 114 (36%) developed a distant metastasis and were counted as failures in the analysis of distant metastasis-free survival (MFS). Logtransformed CIN-scores as continuous variable in Cox regression analysis were associated with MFS and showed a HR of 2.16 (95% confidence interval (CI) 1.53-3.04, P \ 0.0001) for ER-positive and a HR of 1.05 (95% CI 0.70-1.58, P = 0.81) for ER-negative patients. KaplanMeier plots, using three equally sized quantiles of the CINscore, showed a significant difference in MFS-curves in ER-positive patients (Fig. 3a) , but not in ER-negative patients (Fig. 3b) Analysis of the survival curves within the subtypes using the CIN-quantiles suffered from low numbers of patients but similar trends as in the ER subgroups were seen (Fig. 3c, d ). Further analysis also revealed that with regard to prognosis, CIN probably explains the difference between the luminal A and B breast cancer since the difference in MFS between these groups (P = 0.01) was no longer present after correcting for CIN-score (Online Resource Fig. 3 ) (P = 1.00). To validate our association of CIN with prognosis in ER-positive breast cancer, we employed gene expression data of two external datasets [25, 29] with in total 254 ER-positive and 57 ER-negative tumors, from patients who were all lymph-node negative and did not receive systemic treatment after surgery. We developed a 40-gene classifier in our own ER-positive cohort, which, using a Compound Covariate Predictor [30] showed 86% sensitivity and 78% specificity in correctly assigning ''low CIN'' samples. Next, this same classifier was used to predict the status of the ER-positive samples in the external datasets as ''high CIN'' or ''low CIN.'' The CIN-signature significantly stratifies the ER-positive samples in the independent datasets according to outcome (P \ 0.001, Fig. 3e, f) . The same procedure for the ER-negative samples yielded no significant log-rank test (P = 0.23, Online Resource Fig. 4 ). To further explore the biology associated with the CIN process, we correlated transcriptome expression also available from this cohort [15, 16] with the CIN-score.
For this, gene expression patterns were compared between ER-positive samples with the highest CIN-score versus those with the lowest CIN-scores. Pathway analyses were performed using GSEA [20] and global testing [27] . These analyses showed association of CIN with gene sets related to the genomic grade of breast cancer, a CINprofile derived from a diverse set of cancer cell lines, gene sets related to outcome in breast, multiple myeloma and gastric cancer, a wound response signature and gene sets more generally related to cell cycle progression and those involved in pyrimidine metabolism (see Online  Resource Tables 1 and 2 for full details). In addition, genes linked to CIN were enriched for E2F transcription factor binding sites. Pathways negatively associated with CIN were related to cellular differentiation, to extrinsically induced cell death and to T-cell function. The strong relation between CIN and the genomic grade in our cohort prompted us to investigate, on a beforehand unplanned analysis, the influence of CIN after grouping our samples according to the genomic grade signature. It appeared that the CIN-score and genomic grade were independently significant in the analysis for MFS in ER-positive patients in a multivariate analysis (HR 2.29, 95% CI 1.33-3.90, P = 0.002 and HR 1.90, 95% CI 1.19-3.01, P = 0.007 for CIN and genomic grade, respectively). The CIN-score was significantly associated with MFS in the good-grade group (log rank P = 0.004), but not in the poor-grade group; although, the MFS curves based on CIN also in this latter group tended to separate (Online Resource  Fig. 5 ). 
Discussion
Chromosomal instability is a long described concept in tumor biology [1] . In breast cancer, more recent publications describe results based on a CGH copy number data [2, 3, 8, 31] . As shown in Fig. 1 , we observed four major groups of instability profiles; two of these were formerly described by Andre et al. [8] who used 106 samples. They described a group with very few abnormalities (our clustergroup 3) and two groups of samples, which both had the characteristic gains of chr 1q and 8q (our second clustergroup). We identified two additional groups, one characterized by many samples with a gain in chr 1q but without a gain of chr 8q and a group with the opposite pattern.
Although the ER-status of the tumors or the intrinsic subtypes do not fall exclusively in one of the cluster-groups, there are clear non-random patterns. For example group 4 contains 63 samples of which 57 are ER-positive, in which 90% of which have a gain of the q-arm of chr 1, and almost 50% of samples a gain of 16p. This suggests a very different etiology for these cancers than for ER-negative tumors, where only 19% of cases fall in cluster 2 or 4 (which show the chr 1q gain). Since other studies already described specific genomic aberrations which are implicated in the different subtypes of breast cancer [2, 3, 5, 8, 31] , and we knew from our recent work that relatively few specific regions with altered copy number were found to be prognostic (12), our prime objective based on the large variability among samples was to assess the clinical significance of the number of chromosomal abnormalities in individual tumors as well as the biology related to this phenomenon. The four cluster-groups already showed a trend with 118 tumors showing very few abnormalities to tumors having genomes that were greatly rearranged. These observations are backed by the results of a recent publication [10] , which described genome-wide completely paired-end-sequenced breast cancer genomes of cell lines and primary breast tumors; some samples show hardly any events, while others show many aberrations. Thus, notwithstanding specific abnormalities, CIN in itself is not necessarily a common denominator in all breast cancer cases, confirming the notorious heterogeneous nature of breast cancer. The measure for CIN we used here for individual samples showed highly variable CIN-scores and we observed a clear uneven distribution within the different predefined breast cancer subtypes. Significantly higher CIN-scores for ER-negative and triple-negative samples were found, indicating that CIN is a more common event in receptor negative breast cancers. This suggests that this subtype is more prone to accumulation of genomic instabilities. Higher CIN-scores were also observed in basal and luminal B samples, which corroborates previous data [2, 3] , though these were based on low-density CGH data of in total 234 patients. Collectively, accumulating evidence suggests that the breast cancer cell type influences the copy number landscape of a breast cancer. Apparently, not only specific genomic aberrations [3, 11, 32] , e.g., ERBB2 amplification, are linked to a poor outcome in breast cancer, but also the sheer number of chromosomal instabilities is clearly associated with prognosis in ER-positive patients and in patients with a her2/ neu or luminal B subtype (Fig. 3) . These results confirm but also add substantially to the findings of Carter et al. [9] who first reported on the clinical significance of CIN in breast cancer. Literature pertaining CIN and prognosis based on copy number data is scarce. Two publicly available aCGH breast cancer datasets were investigated; the dataset by Chin et al. [3] has 174 samples, but only 11 of these were eligible (ER-positive, lymph-node negative, no adjuvant hormonal, or chemotherapy treated patients), and none of these patients relapsed. The other dataset was from Chin et al. [31] describing 171 patients, of whom 60 were eligible, but only 8 patients showed a relapse. We deemed both these studies not robust enough to validate our results. To be able to confirm our observations in other datasets, we therefore employed two external gene-expression datasets with sufficient cases and appropriate follow-up [25, 29] . In these data, the pure prognostic relevance of CIN inferred from associated differentially expressed genes in ERpositive cases was clearly confirmed (Fig. 3) . Pathway analysis point to an excess of proliferation, including overrepresented E2F-directed transcriptional regulation and increased nucleic acid synthesis, and lack of apoptotic and immune cell responses as prominent features in ERpositive breast cancer. These pathways are considered the traditional hallmarks of unconstrained growth of cells [33] .
The genomic grade signature [25] was found to be the most significant signature associated with CIN, suggesting a strong interaction between CIN and histological tumor grade. Indeed, within our cohort CIN-scores were significantly higher in the poor grade group (Online Resource  Fig. 6 ), an observation also recently reported by Ellsworth et al. [34] , based on a limited amounts of chromosomal areas (n = 26). Since our cohort is a retrospective cohort obtained from various peripheral hospitals we do not have all histological grading available according to current standards. Therefore, we clustered our samples according to the genomic grade profile. Interestingly, the CIN-score and genomic grade were, in a multivariate MFS analysis, independent of each other significantly associated with MFS in ER-positive patients. Of note, since we have analyzed the genomic grade instead of the histopathological grade, these data should be interpreted with caution. The surprising observation that CIN is prognostic in good genomic grade, but not in luminal A samples, while most luminal A samples have a good grade, may be explained by the fact that luminal A samples are not exclusively of good grade; in our cohort, 19% of luminal A samples are of poor grade, while of all good-grade samples, 47% is of luminal A type. Thus, the differences between luminal A and good-grade cohorts probably explain the difference in prognostic value of CIN in these groups. Furthermore, it probably also implies that intrinsic gene expression differences between luminal A and B breast cancers capture the biological and prognostic differences in chromosomal instability quite well. The observation that CIN may be able to discern differences within the good-grade group was also reported by Carter et al. [9] . Their study showed that CIN was able to distinguish outcome in grade 2 tumors in three different datasets (total of 512 patients) and also in grade-1 tumors in a dataset of 161 patients. CIN was not prognostic in the grade-3 samples of the different datasets. This further supports the notion that histopathological grading of well-differentiated tumors in particular can be improved by molecular tools such as gene expression signatures [9, 25] or as described here, the use of SNP copy number data. Taken together, the data suggest that an ER-positive tumor cell with a poor genomic integrity may still phenotypically appear as well differentiated. But despite that appearance, such a tumor is likely to progress. Poorly differentiated tumor cells on the other hand virtually all display an unstable genome.
In conclusion, we confirm that CIN is a prominent event in many breast cancer samples and our observations add to the current paradigm of the role of chromosomal instability in breast cancer. From our work it becomes clear that ERnegative tumors as well as the basal/triple-negative tumors have a highly unstable genome, but unanticipated, this instability does not seem to aggravate prognosis within ERnegative patients. This signifies an association of CIN with the processes regulating the integrity of the genome possibly in the origin, but not in the progression of the disease. In ER-positive, her2/neu, and luminal B tumors the genome is to a lesser degree unstable, but if CIN is present, prognosis is poor. Obviously, the rather extensive methodology to obtain the CIN-score described in this study calls for easier assayable markers to query CIN if it were to be used in diagnostic routine. Nevertheless, assessment of CIN is a useful tool to gain insight into breast cancer biology and may further contribute to a more tailored treatment approach of breast cancer patients.
